The Centers for Medicare & Medicaid Services yesterday released a proposed rule revising requirements for value-based purchasing agreements between states and manufacturers for drugs covered by Medicaid.

According to CMS, the rule would change how manufacturers calculate average manufacturer price for brand name drugs with an authorized generic, and determine whether to include the value of their patient assistance programs when calculating “best price.” It also would revise definitions and reporting requirements for the Medicaid Drug Rebate Program; coordination of benefit and third-party liability rules for certain care and payment in Medicaid and the Children’s Health Insurance Program; and set minimum standards for state Medicaid Drug Utilization Review in an effort to reduce opioid-related fraud, misuse and abuse, among other changes.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The Congressional Budget Office today released its estimate of the budgetary effects of the One Big Beautiful Bill Act, as enacted. CBO projects the law will…
Headline
The Centers for Medicare & Medicaid Services July 17 issued two letters to states regarding policies on continuous eligibility and workforce initiatives.…